The video shows a deposition of Elizabeth Holmes, founder and CEO of Theranos, conducted by the Securities and Exchange Commission (SEC) on July 11, 2017. The SEC is investigating whether Theranos violated federal securities laws. 

During the deposition, Holmes is questioned about Theranos's business and operations, including its technology, personnel, partnerships, and financial situation, particularly during the years 2009-2014. The SEC attorney conducting the deposition is particularly interested in Holmes's knowledge of:

* **Theranos's product development and testing:** The SEC attorney specifically inquiries about the "mini lab" system, a smaller-scale device that ran tests, and its capabilities, particularly in 2010. The questions suggest that the SEC might be investigating whether Theranos misrepresented the capabilities of its technology to investors. 
* **The company's financial situation:** The SEC attorney inquires about the financial statements, specifically a document marked as Exhibit 193, which contains an email from 2010. The SEC attorney is interested in whether Theranos's financial statements were accurate, and if the company was generating revenue as stated. 
* **The company's management structure:** The SEC attorney questions Holmes about the involvement of Sunny Balwani, her former romantic partner and Theranos's COO, in various aspects of the business, including the lab operations, product development, and partnerships with pharmaceutical companies. The questions suggest that the SEC might be investigating whether Balwani was involved in misleading investors or whether Holmes's claims about her own involvement in the business were accurate. 

Holmes's answers are generally vague and hesitant, frequently claiming she doesn't remember details about the company's operations and financial situation. This can be interpreted as a strategy to avoid providing concrete information that could be used against her in a potential criminal trial.  

The deposition suggests that the SEC might be looking into potential criminal charges against Theranos and Holmes, including:

* **Securities fraud:** This is the most likely charge based on the SEC attorney's questions about Holmes's knowledge of Theranos's technology, financial statements, and management structure. If the SEC can demonstrate that Holmes or Theranos made false or misleading statements about the company's technology or financial situation to investors, then they could be charged with securities fraud. 
* **Wire fraud:** This charge could be pursued if the SEC can demonstrate that Holmes or Theranos used a wire communication device, such as a telephone or email, to defraud investors. 
* **Mail fraud:** This charge could be pursued if the SEC can demonstrate that Holmes or Theranos used the mail to defraud investors, for example, by sending out promotional materials or other correspondence containing false or misleading statements. 

The deposition is just one piece of evidence that the SEC is using in its investigation. If the SEC determines that Theranos violated federal securities laws, it could pursue civil charges against the company and Holmes. Additionally, the SEC could refer its findings to the Department of Justice (DOJ) for possible criminal prosecution.